OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

Charity Registration No. 1182637 (England and Wales)

Charity Registration No. SC049948 (Scotland) Company Registration No. CE016951 (England and Wales)

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION LEGAL AND ADMINISTRATIVE INFORMATION

Trustees David Oxnam (Chair of the Board of Trustees) Sarah Curtis Angela Polanco (Appointed 13 June 2025) Laura Thomas (Appointed 28 April 2026) Angelo Ercia (Appointed 11 September 2025) Catherine Anderson (Appointed 11 September 2025) Bushra Khawaja (Appointed 11 September 2025) Natalie Agboeze (Appointed 11 September 2025) Andy Donnelly (Appointed 11 September 2025) Ngozi Ayanru (Appointed 11 September 2025) Hollie Shears (Appointed 11 September 2025) Chief Executive Ashley Ball-Gamble Charity number 1182637 (England and Wales) SC049948 (Scotland) Company number CE016951 Operating name CCLG Principal address Century House 24 De Montfort Street Leicester LE1 7GB Auditor Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT Bankers HSBC Bank Plc 2-6 Gallowtree Gate Leicester LE1 1DA Scottish Widows Bank Plc PO Box 12757 67 Morrison Street Edinburgh EH3 8YJ CAF Bank Ltd 25 Kings Avenue Kings Hill Kent ME19 4JQ

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION CONTENTS

Page
Trustees' report 1 - 12
Independent auditor's report 13 - 15
Statement of financial activities 16
Balance sheet 17
Statement of cash flows 18
Notes to the financial statements 19 - 33

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

The trustees of The Children’s Cancer and Leukaemia Group, trading as CCLG: The Children & Young People’s Cancer Association (CCLG), are pleased to present their annual report and financial statements for the year ended 31 December 2025.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity’s governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (“FRS 102”), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

OBJECTIVES AND ACTIVITIES

The objectives of CCLG as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

  1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.

  2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.

  3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.

  4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

Expert clinical work

CCLG is the UK and Ireland's professional association for all those involved in the treatment, care and research of children and young people (aged 0-25) with cancer. At the end of 2025, our membership stood at more than 1,800 members.

We bring together the experts in children and young people's cancer through our professional membership, creating a powerful national network driving progress. Together, we shape better treatment and care: developing guidelines, sharing expertise, offering advice, leading groundbreaking research, and creating essential resources and education for professionals.

Our collective expertise sets the standard, advising, influencing, and advocating for excellence locally, nationally, and globally.

We carry out a wide range of activities to support our professional members, including:

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

for some childhood cancers and using treatment guidelines is vital for ensuring equality of access to what is regarded by national experts as the best possible treatment currently available. CCLG members regularly review guidance and recommendations to cover all of the major children's cancers, including leukaemia. Our guidelines are written by national experts in the field of each tumour type, usually by members of the relevant CCLG Special Interest Group. Guidance and recommendations draw on evidence from international research and treatment protocols, and the aim is to ensure guidance is consistent with the standard of care internationally.

Our members are dedicated to ensuring that children and young people have a greater chance of survival and a better life after treatment.

Information and guidance

We support children and young people with cancer and their families in a variety of different ways:

Research

The incredible progress in treating cancer in children and young people is built on decades of dedicated research and clinical trials. Over the last 40 years, this research has transformed survival rates, with more than 80% of children now being cured. CCLG has been at the heart of this progress, driving research and collaboration to improve outcomes.

But there is still more to do. Some cancers remain difficult to treat, and many existing treatments cause longterm and life-changing side effects. We need more research to improve survival rates, develop kinder treatments, and ensure the best possible quality of life for children and young people after cancer.

At CCLG, we fund and support research across the entire cancer pathway-from diagnosis and treatment to patient experience and survivorship. We make sure research meets the real needs of children and young people with cancer, their families, and those who care for them. In 2022, we identified the top 10 priorities for childhood cancer research, shaped by the voices of children, young people, parents, and professionals.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

Collaboration is at the heart of what we do. We work with leading researchers and organisations to drive forward impactful studies, ensuring the best projects and brightest minds receive funding. We partner with other charities to maximise investment in research and use our expertise to support smaller charities in funding high-quality studies with real impact.

We lead the UK Children's and Teenage, Young Adult & Germ Cell Tumour Cancer Clinical Research Groups, part of the national UK3CR network, shaping and overseeing clinical research across the UK. Our Special Interest Groups bring together experts to share knowledge and plan future research.

We create opportunities for discovery. We organise and support scientific meetings, ensuring vital research is shared, discussed, and developed. We empower our professional membership to be actively involved in shaping research. Our Early Career Research Network and dedicated funding for nurses, allied health professionals, and early-career researchers ensure the next generation of childhood cancer experts can continue to push boundaries and drive progress.

Our research strategy sets out our vision for the future of children and young people's cancer research - because every child deserves the best possible chance.

We work to share information about research, including results and outcomes, with the public, including through our popular research blog and a series of webinars on a variety of research topics.

Since 2017, CCLG has been a member of the Association of Medical Research Charities, demonstrating our commitment to funding high-quality, world class research and confirming the high standard of the processes we use to select and fund research.

Policy and advocacy

We use our expertise and influence to make things better. By campaigning and advocating for children and young people with cancer, their families, and the professionals who support them, we're driving change where it matters most.

Working alongside politicians, governments, the NHS, and other organisations, we're pushing for progress and shaping a brighter future for young lives.

We combine our professional membership's expertise along with the voice of lived experience to develop position statements and policy ideas, shape campaigns, and respond to consultations from governments, the NHS, and other bodies about plans, policies, research or services for children and young people with cancer.

We also work in partnership with other organisations to ensure that children and young people's cancer has a strong, unified voice. We are a founding member of the Children and Young People's Cancer Coalition, and our Chief Executive is the current Chair. We also contribute to wider policy work where it affects children and young people with cancer, including through our membership of Cancer 52 (the alliance for rare and less common cancers), the Association of Medical Research Charities, the Wales Cancer Alliance, and the One Cancer Voice coalition.

Our Chief Executive was invited to be part of the Government's Children and Young People's Cancer Taskforce, working with the Department of Health and Social Care to drive forward improvements in the treatment and care of children, teenagers and young adults with cancer, to develop recommendations for children and young people’s cancer as part of the government’s National Cancer Plan, published in early 2026.

Early diagnosis

Early diagnosis saves lives. Spotting cancer in children and young people early means better outcomes, fewer long-term effects, and the best chance of survival. That's why we're dedicated to making sure children and young people with symptoms of cancer get a diagnosis as quickly as possible.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

We raise awareness of the signs and symptoms, empowering families and communities to act sooner. For healthcare professionals, we provide tools and resources to support informed decisions about tests and scans. Together, we're working to ensure every child and young person gets the timely diagnosis they need.

We have information about the signs and symptoms of cancer in children and young people, and information and resources for healthcare professionals about diagnosing cancer in children and young people.

During the year we continued to focus on research to generate a new evidence base on how cancer presents in children and young people, as well as the routes to diagnosis, to inform a new national campaign, Child Cancer Smart, which launched during the year. Child Cancer Smart aims to raise awareness of the signs and symptoms of children's cancer and provide tools for GPs and other healthcare professionals to support them to make timely and accurate referrals.

We measure our success in achieving our objectives in a number of ways:

ACHIEVEMENTS AND PERFORMANCE

Around 1,800 children (aged 0-14) and a further 2,300 teenagers and young adults (aged 15-25) are diagnosed with cancer each year in the UK. Although overall five-year survival for cancer in children and young people is now over 80%, for some cancers there have not been such dramatic improvements in survival, and even where treatment is successful, many survivors must contend with life-long and life-limiting side effects. Highlights of our achievements during the year are set out under each of the strategic goals defined in our organisational strategy.

During the year, Children’s Cancer and Leukaemia Group and Teenagers and Young Adults with Cancer (TYAC) merged their memberships to form a new professional association which brings together healthcare professionals and researchers to achieve the best possible care and support for children, teenagers and young adults with cancer. TYAC had formerly merged with CCLG in 2019, but by bringing the two memberships fully together, recognising the overlap between them, this approach will enhance our membership offer, especially to those who work across the patient age groups, and strengthen the work we do across research, health information, and early diagnosis.

At the same time, we re-branded the organisation to become ‘CCLG: The Children & Young People’s Cancer Association’. This new name, along with a new website, fresh branding and a change to the way we talk about our work, will further raise our profile and grow fundraising income to support our work.

Providing leadership and expertise for the treatment and care of children and young people with cancer

As the UK and Ireland's professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children's cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. Highlights for 2025 include:

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis and make appropriate onward referrals.

Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the UK are larger, at a more advanced stage and require more therapy than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2025:

Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives. We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2025:

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the children and young people's cancer community. Our Research Strategy outlines our plans to fund and support innovative world-class research into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements.

We fund research directly, and work with partner charities to support them to fund the best possible research, using our well-established research funding expertise, experience and infrastructure.

In total, between our own research funding and that of the partners we work with, 29 new research projects totalling around £3.8 million were funded in 2025. Grants awarded cover a wide range of cancer types, projects focusing on different parts of the cancer experience, and covering a range of different types of research.

In 2025:

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families, and improve treatment and care for children and young people with cancer.

Our Special Named Fund programme continued to grow. After their cancer experiences, families sometimes consider setting up their own charity. For many, our Special Named Funds may be a great alternative. We support families to achieve their fundraising objectives, while taking away the administrative burden of setting up and running a charity. At the end of the year, there were approximately 110 Special Named Funds at CCLG (2024: 104), each raising funds to support research into a specific type of childhood cancer.

We continued to develop our internal fundraising strategy, which aims to ensure we are able to sustain our income growth and continue to deliver on our charitable objectives: funding research, supporting families and ensuring that all young patients receive the best possible treatment and care. The strategy includes investment in fundraising to develop our activity in key areas, as well as building on previous investments in data infrastructure which will allow us to make more strategic, data-driven decisions around fundraising activity.

We are hugely grateful to all those who chose to support CCLG, by making a donation, taking part in an event, or organising their own fundraiser during the year.

Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public, we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into children and young people’s cancer. We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials. Our supporters can also sign up to make regular donations. We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities. We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations.

Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies. CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities.

Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

FINANCIAL REVIEW

Transactions for the year ended 31 December 2025 fall into roughly the same categories as in previous years.

Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, funding from partner charities such as The Little Princess Trust to support research projects, and legacy income. We are grateful to Young Lives vs Cancer, Teenage Cancer Trust and The Little Princess Trust for their support of specific areas of our work.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants. Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity.

Our overall income increased by £570,640, compared with the year ending December 2024. The majority of this is comprised of an increased in fundraising income from donations and legacies, and an increase in research funding through our partnership with The Little Princess Trust.

CCLG has a number of restricted funds. Internal records are kept according to requirements for restriction, i.e. disease-specific donations for research into a specific type of cancer, or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

Expenditure increased in 2025 by £678,666 compared to 2024. This mainly reflects an increase in research expenditure, some of which was funded through restricted reserves, the increased cost of holding events (reflecting increases in costs in the event industry, including in staffing), particularly our Annual Conference which is now a major event requiring a large venue, and through increased staffing costs.

We ended the year with an overall deficit of £601,378. There was a deficit of unrestricted income and expenditure of £172,822, compared with a deficit of £428,556 in restricted income and expenditure. This reflects our previous commitment to increasing our investment in research, and the fact that much of our restricted income is restricted to research into specific types of cancer, building over several years until there are sufficient funds available to invest in high-quality, impactful research projects.

Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. The COVID-19 pandemic followed by a period of global economic uncertainty and inflationary pressure has highlighted the importance of an appropriate reserves policy. It is important we continue to hold a level of reserves which can sustain our activity until we have a fuller picture of what the external environment, particularly in respect of fundraising and charitable giving, looks like in the medium-term.

We have plans in place to ensure CCLG is 'fit for the future' and our reserves policy will ensure we are able to meet those plans. At the end of the year, we have reviewed our reserves policy and aim to hold a target level of free reserves (unrestricted fund less tangible fixed asset) of £250,000, which the Trustees consider to be approximately three months of core expenditure, including staff salaries, accommodation costs and general running costs, based on the 2026 budget.

The Trustees consider it prudent to balance the investment of reserves into charitable activity to meet the needs of our beneficiaries and fulfil the wishes of our donors and supporters. Having a reserves policy based on a range rather than a fixed figure, as previously, gives us the flexibility to be more responsive to appropriate opportunities for charitable investment.

Total reserves at 31 December 2025 were £2,193,822 (2024: £2,795,200) of which £1,939,962 (2024: £2,368,518) are restricted and £253,860 (2024: £426,682) are unrestricted. As at 31 December 2025 the charity's free reserves totalled £212,417 (2024: £399,452) which is slightly below the target set out in the reserves policy. Given the current economic uncertainty, the trustees consider it prudent to balance the investment of reserves into our charitable activity whilst ensuring sufficient funds are available to ensure the charity is a 'going concern' and able to meet its commitments and will work to ensure that free reserves are built back to meet the reserves policy while also investing appropriately in charitable activities. The Trustees continue to keep the reserves policy under review to ensure that CCLG is 'fit for the future’.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

Our restricted reserves appear high, at £1,939,962 at the end of 2025. Much of our restricted fundraising income is raised by families, ring-fenced for research into specific types of childhood cancer. Research requires significant investment, and thus many of our funds grow over the course of several years before a large sum of money is awarded in the form of a research grant. Our restricted reserves comprise a large number of specific restricted funds which are ring-fenced to a specific purpose and therefore cannot be used for general activities. Levels of funds are reviewed on a regular basis and spent on charitable activities as soon as sufficient funds are available. Our restricted reserves decreased at the end of 2025 compared with 2024, representing our commitment to increase our investment in research, and we expect to see a further decrease at the end of 2026 as we continue to support a wider range of research projects and explore collaborative opportunities with other funders.

Investment policy

The Trustees previously reviewed our plans for investments to consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the ongoing uncertainty of the financial impact of the costof-living crisis, no further action has been taken on investments.

Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

Risk Management

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

Following a review of the risk register and the controls in place, the key risks facing the charity are:

FUTURE ACTIVITIES

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives for children and young people with cancer, and their families, as the ultimate beneficiaries. As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and providing specialist advice to commissioners of healthcare services and others. The Executive continues to consider ways that CCLG can advance education and professional development and share and guide best practice.

Key planned activity for the next 12 months includes:

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Children’s Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. In 2019, a new CIO (registration number 1182637) was formed, with the activities, assets and liabilities of the previous charity transferred to the CIO. The charity’s governing instrument is the Constitution, and the CIO was first registered in February 2019. In 2020, the CIO became registered with the Scottish Charity Regulator (registration number SC049948). In 2025, CCLG began operating as CCLG: The Children & Young People’s Cancer Association.

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for ensuring the charity meets its objectives, delivers on its strategy, has oversight of all activities of the charity, and managing the charity. There are a minimum of two and a maximum of twelve trustees.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate. Regard is given to the training and development needs of any trustees that may arise.

During the year we undertook an open recruitment exercise to increase the number of Trustees, seeking to expand the range of views, professional backgrounds and skills of those on the Board.

The trustees come from a range of professional backgrounds and bring new skills and highly relevant experience. Trustees serving during the year were: David Oxnam (Chair of Board of Trustees) Rachel Wilcox (resigned 28 April 2026) Sarah Curtis Angela Polanco (appointed 13 June 2025) Laura Thomas (appointed 28 April 2026) Angela Ercia (appointed 11 September 2025) Catherine Anderson (appointed 11 September 2025) Bushra Khawaja (appointed 11 September 2025) Natalie Agboeze (appointed 11 September 2025) Andy Donnelly (appointed 11 September 2025) Ngozi Ayanru (appointed 11 September 2025) Hollie Shears (appointed 11 September 2025)

The Chief Executive is responsible for the day-to-day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 12 to the accounts.

Key Management Personnel during the year were: Ashley Ball-Gamble (Chief Executive) Claire Shinfield (Director of Engagement) Vicki Brunt (Head of Fundraising) Sarah Evans (Head of Research) Phil Welsh (Head of Communications) Jeanette Hawkins (Chief Nurse) Jo Stark (Chief Nurse)

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE’S CANCER ASSOCIATION

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

STATEMENT OF TRUSTEES’ RESPONSIBILITIES

The trustees are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities (Accounts and Reports) Regulations 2008, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity’s constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

………………………………… David Oxnam

Chair of the board of trustees

17-09-2026 Date: ……………………………

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Opinion

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the ‘charity’) for the year ended 31 December 2025 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 12, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under these acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charity.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and noncompliance with laws and regulations, our procedures included the following:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP discussing amongst the engagement leam how and where fraud might (￿CUr in the financial stslemenls and any potential indicators of fraud. Audlt response to rlsks of Irregularftles Identlfied Our procedures to respond to risks identified induded the following.. perfoming audit work over revenue re￿gnitson induding analytical procedu￿$ and substsnttve lesls of detail of a sample of revenue transactions," and reviewing financial statement disdosures and lesting to supporbrwj documentation to assess compliance with applicable laws and r￿Ulations", and enquiry of Charty stsff responsible for compliance to identify any instsnces of nor￿cOmplIance wlh laws and regulations". and enquiry of management. those charged with govemance and other relevant parties around actual and potential lrtigats.on claims", and reviewing minutes of meetings of those charged wrth govemance", and perfomiing audit work over the risk of management override of controls. induding testing of joumal entries and other adjustments for appropriateness. evaluating the business rationale of significant transactions outside the nomial course of business and rewewng accounts.ng estimates for bias", and communicating identified laws and regulations and potential fraud risks lo all engagement team members and assessing whether there are any indications of fraud or nowomplian(£ wlh laws and regulations throughout the audit. Because of the inherent limitations of an audit. the￿ is a risk that we wll not delecl all irregularrties, induding those leading lo a material misstatement in the financial statements or non-￿mplianCe wf(h regulation. This risk increases the mDre that compliance a law or regulats'on is removed from the events and transactions refiected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularits.es occurring due to fraud rather Ihan eThor, as fraud involves intentional COn￿alMent, forgery, collusion, omission or misrepresentation. A further description of our responsibilities is available on the Finanaal Reporting Council's website at.. https'.11 www.frc.org.uklauditorsresponsibilities. This description forms part of our auditorfs report. Use of our report This report is made solely to the chanty's trustees. as a body, in accordance with Part 4 of the Charities IAccounts and Reports) Regulations 2008, and Regulation 10 of the Charities Accounts {Scotland} Regulatlons 2006. Our audit work has been undertaken so that we might slate to the charrtls trustees those matters we are required lo slate lo them in an audilor5' report and for no other purpose. To the fullest extent perrnitted by law, we do not accept or assume responsibility lo anyone other than the d)arrty and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have fomied. Newby Cast]eman LLP Chartered Accounlanls ststutory Auditor West Walk Building 110 Règent Road Leicester LE17LT 17 September 2026 Newby Castleman LLP is eligible lo act as an audrtor in terms of section 1212 of the Companie5 Act 2006. 15-

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2025

Unrestricted
Restricted
funds
funds
2025
2025
Notes
£
£
Income from:
Donations and legacies
3
1,029,852
653,622
Charitable activities
4
573,310
3,185,467
Investments
5
52,820
-
Total
1,655,982
3,839,089
Expenditure on:
Raising funds
6
491,211
6,730
Charitable activities
7
1,337,593
4,260,915
Total
1,828,804
4,267,645
Net expenditure for the year/
Net movement in funds
(172,822)
(428,556)
Reconciliation of funds
Total funds brought forward
426,682
2,368,518
Total funds carried forward
253,860
1,939,962
Total
2025
£
1,683,474
3,758,777
52,820
5,495,071
497,941
5,598,508
6,096,449
(601,378)
2,795,200
2,193,822
Total
2024
£
1,581,702
3,272,798
69,931
4,924,431
394,603
5,023,180
5,417,783
(493,352)
3,288,552
2,795,200

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION BALANCE SHEET

AS AT 31 DECEMBER 2025

2025 2024
Notes £ £ £ £
Fixed assets
Tangible assets 14 41,443 27,230
Current assets
Stocks 15 37,508 46,019
Debtors 16 3,279,726 3,387,399
Cash at bank and in hand 2,861,722 4,480,787
6,178,956 7,914,205
Liabilities
Creditors: amounts falling due within one
year 17 (2,991,753) (3,704,081)
Net current assets 3,187,203 4,210,124
Total assets less current liabilities 3,228,646 4,237,354
Creditors: amounts falling due after
more than one year 18 (1,034,824) (1,442,154)
Total net assets 2,193,822 2,795,200
The funds of the charity
Restricted funds 20 1,939,962 2,368,518
Unrestricted funds 21 253,860 426,682
Total charity funds 2,193,822 2,795,200

17-09-2026

The financial statements were approved and authorised for issue by the board of trustees on ......................... and are signed on its behalf by:

..............................

David Oxnam (Chair of the Board of Trustees)

Trustee

The notes on pages 19 - 33 form part of these financial statements.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2025

Note
Cash flows from operating activities
Cash absorbed by operations
26
Investing activities
Purchase of tangible fixed assets
Investment income received
Net cash generated from investing
activities
Net cash used in financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
2025
£
£
(1,645,138)
(26,747)
52,820
26,073
-
(1,619,065)
4,480,787
2,861,722
2024
£
£
(689,399)
(5,454)
69,931
64,477
-
(624,922)
5,105,709
4,480,787

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies

Charity information

The Children's Cancer and Leukaemia Group is governed by its Constitution.

1.1 Basis of preparation

The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (“FRS 102”), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies

(Continued)

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Computer equipment, furniture and fixtures 5-10 years

1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity’s activities are valued at their service potential, which the charity considers to be the cost of the materials.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.10 Financial instruments

Financial instruments are recognised in the charity’s balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies

(Continued)

1.11 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity’s accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:

Allocation of support costs

The allocation of support costs is sensitive to changes in the level of work undertaken on each activity by the charity. The allocation is reassessed annually and amended when necessary to reflect current estimates.

3 Income from donations and legacies

Unrestricted
Restricted
funds
funds
2025
2025
£
£
Donations
638,498
653,622
Legacies
391,354
-
1,029,852
653,622
Total
Unrestricted
funds
2025
2024
£
£
1,292,120
626,417
391,354
327,406
1,683,474
953,823
Restricted
funds
2024
£
627,879
-
627,879
Total
2024
£
1,254,296
327,406
1,581,702

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

4 Income from charitable activities

Unrestricted Restricted
Total
Unrestricted
Restricted
funds
funds
funds
funds
2025
2025
2025
2024
2024
£
£
£
£
£
Registration fees for meetings
and other project expenditure
266,100
3,597
269,697
238,380
11,750
Member subscriptions and
publication payments
188,039
-
188,039
152,428
-
Grant income for research and
operations
119,171
3,101,014
3,220,185
72,803
2,701,486
CLIC Sargent chief nurse
funding
-
80,856
80,856
-
95,951
573,310
3,185,467
3,758,777
463,611
2,809,187
5
Income from investments
Unrestricted
Total
Unrestricted
funds
funds
2025
2025
2024
£
£
£
Interest
52,820
52,820
69,931
6
Expenditure on raising funds
Unrestricted
Restricted
Total
Unrestricted
Restricted
funds
funds
funds
funds
2025
2025
2025
2024
2024
£
£
£
£
£
Costs of raising funds
Fundraising platform fees
27,643
-
27,643
26,222
-
Website
2,644
6,730
9,374
2,293
14,934
Fundraising, marketing
and publicity costs
260,481
-
260,481
138,031
36,778
Support costs (note 10)
200,443
-
200,443
176,345
-
491,211
6,730
497,941
342,891
51,712
Restricted
funds
2024
£
11,750
-
2,701,486
95,951
Total
2024
£
250,130
152,428
2,774,289
95,951
2,809,187 3,272,798
Total
2024
£
69,931
Total
2024
£
26,222
17,227
174,809
176,345
394,603

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

7 Expenditure on charitable activities

Activities
undertaken
directly
Note 8
£
Support for research
292,347
Information for patients and families
59,307
Improving treatment and care
505,943
857,597
Unrestricted funds
Restricted funds
Grant
funding
Note 9
£
3,897,659
-
-
3,897,659
Support
Costs
Note 10
£
207,495
309,790
325,967
843,252
Total
2025
£
4,397,501
369,097
831,910
5,598,508
1,337,593
4,260,915
5,598,508
Total
2024
£
3,967,943
342,090
713,147
5,023,180
1,103,627
3,919,553
5,023,180

8 Expenditure on activities undertaken directly

Support for
research
Information
for patients
and families
Improving
treatment
and care
£
£
£
Staff costs
217,604
-
-
Other tumour specific expenditure
65,369
-
-
Contact magazine expenses
-
24,249
-
Other publication expenses
-
20,996
-
Website
9,374
14,062
14,063
Cost of meetings
-
-
443,841
Travel expenses
-
-
16,359
Membership support costs
-
-
24,462
Other expenses
-
-
7,218
292,347
59,307
505,943
Total
2025
£
217,604
65,369
24,249
20,996
37,499
443,841
16,359
24,462
7,218
857,597
Total
2024
£
205,335
156,255
20,306
20,446
68,912
344,837
16,893
24,094
6,540
863,618

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

9
Expenditure on grant funding
Support for
research
£
Grants to institutions:
University of Birmingham
184,854
University of Surrey
287,410
Newcastle University
547,097
UCL Institute of Child Health
838,513
University of Nottingham
351,130
University of Bristol
55,715
Great Ormond Street
19,700
University of Southampton
158,482
University Hospital of Wales
-
University of Glasgow
100,000
University of York
191
University of Cambridge
375,205
Institute of Cancer Research
197,661
University of Leeds
32,608
University of Manchester
53,892
University of Oxford
60,000
University College Cork
(438)
Swansea University
-
Birmingham Children's Hospital
79,888
King's College London
-
The Open University
22,104
University of Edinburgh
100,000
Imperial College London
73,299
Sheffield Children`s Foundation Trust
-
University Hospitals Bristol and Weston NHS Trust
-
University of East Anglia
-
University College Dublin
237,806
University of Strathclyde
22,780
Alder Hey Children's Hospital NHS Foundation Trust
93,475
Institut de Recerca Sant Joan de Déu
6,287
3,897,659
Total
2025
£
184,854
287,410
547,097
838,513
351,130
55,715
19,700
158,482
-
100,000
191
375,205
197,661
32,608
53,892
60,000
(438)
-
79,888
-
22,104
100,000
73,299
-
-
-
237,806
22,780
93,475
6,287
3,897,659
Total
2024
£
350,207
112,216
(474)
345,890
81,543
61,069
702,390
-
(33,114)
216,831
252,682
493,268
186,225
61,556
-
99,701
4,950
230,943
-
74,458
(94)
-
-
19,949
19,743
124,360
-
-
-
-
3,404,299

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

Negative amounts represent an underspend on grants previously made, returned to CCLG.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

10 Expenditure on support costs

Basis of allocation
Staff costs
1
Depreciation & loss on disposal
1
Occupancy expenses
1
Postage
1
Staff training
1
Professional fees
1 / *2
Analysed between
Raising funds
Charitable activities
2025
£
824,901
12,534
141,412
15,993
7,374
41,481
1,043,695
200,443
843,252
1,043,695
2024
£
716,066
9,228
131,991
15,896
8,571
49,856
931,608
176,345
755,263
931,608

*1 Support costs, excluding governance costs, have been allocated as follows:

Cost of raising funds 20% (2024 - 20%) Charitable activities Support for research 20% (2024 - 20%) Information for patients and families 30% (2024 - 30%) Improving treatment and care 30% (2024 - 30%)

*2 Professional fees include governance costs of £41,481 (2024 - £49,856). Governance costs have been allocated as follows:

Charitable activities Support for research 17% (2024 - 17%) Information for patients and families 22% (2024 - 22%) Improving treatment and care 61% (2024 - 61%)

The amount charged to the SOFA in respect of auditor's remuneration was: - statutory audit £10,764 (2024 - £10,140)

11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

12 Trustees

Except for the disclosures below, none of the trustees received any remuneration, benefits or reimbursements from the charity during the year, or in the previous year.

During the year, expenses were reimbursed to the following trustees: N Agboeze was reimbursed £104 (2024 - £Nil) for meeting expenses; H Shears was reimbursed £104 (2024 - £Nil) for meeting expenses; A Donnelly was reimbursed £130 (2024 - £Nil) for meeting expenses.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

13
Employees
The average monthly number of employees during the year was:
Total
Employment costs
Wages and salaries
Social security costs
Other pension costs
The number of employees whose annual remuneration (excluding pension
contributions) was more than £60,000 is as follows:
£60,001 - £70,000
£70,001 - £80,000
£100,001 - £110,000
£110,001 - £120,000
Remuneration of key management personnel
The remuneration of key management personnel, is as follows.
Aggregate compensation
2025
Number
26
2025
£
850,097
104,114
88,294
1,042,505
2025
Number
-
1
-
1
2025
£
418,207
2024
Number
24
2024
£
769,767
75,889
75,745
921,401
2024
Number
1
-
1
-
2024
£
377,924

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

14
Tangible fixed assets
Computer
equipment,
furniture
and fixtures
£
Cost
At 1 January 2025
95,484
Additions
26,747
Disposals
(21,239)
At 31 December 2025
100,992
Depreciation and impairment
At 1 January 2025
68,254
Depreciation charged in the year
12,534
Eliminated in respect of disposals
(21,239)
At 31 December 2025
59,549
Carrying amount
At 31 December 2025
41,443
At 31 December 2024
27,230
15
Stocks
2025
£
Merchandise stock
16,443
Educational literature
21,065
37,508
Total
£
95,484
26,747
(21,239)
100,992
68,254
12,534
(21,239)
59,549
41,443
27,230
2024
£
23,412
22,607
46,019

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

16 Debtors

Amounts falling due within one year:
Trade debtors
Grant debtors
Rent deposit
Prepayments and accrued income
Accrued legacy income
Amounts falling due after more than one year:
Grant debtors
Total debtors
Creditors: amounts falling due within one year
Deferred income
Trade creditors
Grant creditors
Accruals
2025
£
40,243
1,959,926
18,600
322,048
248,000
2,588,817
2025
£
690,909
3,279,726
2025
£
51,599
101,292
2,794,724
44,138
2,991,753
2024
£
25,298
2,239,464
18,600
238,554
283,500
2,805,416
2024
£
581,983
3,387,399
2024
£
32,241
8,729
3,622,339
40,772
3,704,081

17 Creditors: amounts falling due within one year

Deferred income includes income received in respect of meetings to be held in the next financial year.

18 Creditors: amounts falling due after more than one year

2025 2024
£ £
Grant creditors 1,034,824 1,442,154

19 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees.

The amount of contribution recognised in unrestricted expenditure was £88,294 (2024 - £75,745).

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

20 Restricted funds

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

Balance at
1 January
2025
£
Tumour specific funds
1,538,874
CCLG Prize
364
General research fund
15,920
Adam Hay fund
11,262
CCLG Senior Members Group
7
PODC
2,100
The Little Princess Trust fund
6,200
Treatment Guidelines fund
614
TYAC Lisa Thaxter
2,040
Child Cancer Smart
35,190
PORT
420
CCLG Research Network
Partner Charity
15,000
Neuroblastoma Nursing Group
1,500
PODC - Iraq Fund
7,891
Young Lives vs Cancer Chief
Nurse Funding
589
Health Information
16,920
TYAC General Restricted
1,000
TYAC Research
66,496
Projects Restricted Fund
646,131
2,368,518
Movement in funds
Income
Expenditure
£
£
652,532
(775,921)
-
-
-
-
-
-
-
-
984
-
3,101,014
(3,101,014)
-
-
-
-
-
-
-
-
-
-
-
-
3,203
(42)
80,856
(84,252)
-
-
-
-
-
-
500
(306,416)
3,839,089
(4,267,645)
Transfers
Balance at
31 December
2025
£
£
-
1,415,485
-
364
-
15,920
-
11,262
-
7
-
3,084
-
6,200
-
614
-
2,040
-
35,190
-
420
-
15,000
-
1,500
-
11,052
2,807
-
-
16,920
-
1,000
-
66,496
(2,807)
337,408
-
1,939,962

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

20 Restricted funds

(Continued)

Balance at
1 January
2024
£
Tumour specific funds
1,605,293
CCLG Prize
364
General research fund
5,670
Adam Hay fund
11,262
CCLG Senior Members Group
7
PODC
6,850
POTG
2,156
The Little Princess Trust fund
6,200
Treatment Guidelines fund
614
TYAC Lisa Thaxter
21,632
Child Cancer Smart
37,786
PORT
420
CCLG Research Network
Partner Charity
-
Neuroblastoma Nursing Group
1,500
PODC - Iraq Fund
9,694
Young Lives vs Cancer Chief
Nurse Funding
2,332
Health Information
16,920
TYAC General Restricted
1,000
TYAC Research
66,496
Projects Restricted Fund
1,102,398
2,898,594
Movement in funds
Income
Expenditure
£
£
1,006,365
(1,072,784)
-
-
10,250
-
-
-
-
-
915
(5,665)
10,170
(16,449)
2,314,140
(2,314,140)
-
-
-
(19,592)
-
(2,596)
-
-
15,000
-
-
-
850
(2,653)
79,376
(81,119)
-
-
-
-
-
-
-
(456,267)
3,437,066
(3,971,265)
Transfers
Balance at
31 December
2024
£
£
-
1,538,874
-
364
-
15,920
-
11,262
-
7
-
2,100
4,123
-
-
6,200
-
614
-
2,040
-
35,190
-
420
-
15,000
-
1,500
-
7,891
-
589
-
16,920
-
1,000
-
66,496
-
646,131
4,123
2,368,518

Transfers have been made into restricted funds from unrestricted funds to underwrite a cash deficit on a fund.

Tumour specific funds

Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

CCLG Prize

Represents income received from donors to fund the CCLG Prize.

General research fund

Represents income received from donors with a specific request that the funds are used for research purposes.

Adam Hay fund

This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

CCLG Senior Members Group

Represents income received from the Senior Members’ Group to be used for their activities.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

20 Restricted funds

(Continued)

PODC

Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

POTG

Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

The Little Princess Trust fund

Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

Treatment Guidelines fund

Represents a grant received for the development of rare endocrine tumour guidelines.

TYAC Lisa Thaxter

Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

Child Cancer Smart

Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

PORT

Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

CCLG Research Network Partner Charities

Represents income received from other charities to fund and support research projects.

Neuroblastoma Nursing Group

Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

PODC - Iraq Fund

Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

Young Lives vs Cancer Chief Nurse Funding

Funding for the Chief Nurse role and associated projects. Funds were transferred from our Projects Restricted Funds to the Young Lives vs Cancer Chief Nurse Funding to underwrite a cash deficit on the fund. The related expenditure is in line with the restricted purpose of the Projects Restricted Funds.

Health Information

Funds received to support the production of health information for patients and families.

TYAC General Restricted

Fundraising and donations to support work specifically for teenagers and young adults with cancer.

TYAC Research

Income restricted to support research projects into teenage and young adult cancer.

Projects Restricted Funds

Income restricted to support specific projects including work related to research. Funds were transferred from our Projects Restricted Funds to the Young Lives vs Cancer Chief Nurse Funding to underwrite a cash deficit on the fund. The related expenditure is in line with the restricted purpose of the Projects Restricted Funds.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

21
Unrestricted funds
Movement in funds
Balance at
1 January
2025
Income Expenditure
£
£
£
General funds
426,682
1,655,982
(1,828,804)
Movement in funds
Balance at
1 January
2024
Income Expenditure
£
£
£
General funds
389,958
1,487,365
(1,446,518)
22
Analysis of net assets between funds
Unrestricted
funds
2025
£
Fund balances at 31 December 2025 are represented by:
Tangible assets
41,443
Current assets/(liabilities)
212,417
Long term liabilities
-
253,860
Unrestricted
funds
2024
£
Fund balances at 31 December 2024 are represented by:
Tangible assets
27,230
Current assets/(liabilities)
399,452
Long term liabilities
-
426,682
Transfers
Balance at
31 December
2025
£
£
-
253,860
Transfers
Balance at
31 December
2024
£
£
(4,123)
426,682
Restricted
Total
funds
2025
2025
£
£
-
41,443
2,974,786
3,187,203
(1,034,824)
(1,034,824)
1,939,962
2,193,822
Restricted
Total
funds
2024
2024
£
£
-
27,230
3,810,672
4,210,124
(1,442,154)
(1,442,154)
2,368,518
2,795,200

23 Events after the reporting date

The charity was notified of an additional legacy during a prior year. The timing and amount of the legacy income is uncertain as at the balance sheet date and therefore no income relating to this legacy has been recognised in these accounts.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

24 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Within one year
Between two and five years
2025
£
39,096
98,214
137,310
2024
£
39,096
137,310
176,406

Amounts recognised in the SOFA as an expense during the period in respect of operating lease arrangements are £39,096 (2024 - £37,471).

25 Related party transactions

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 12 to the financial statements.

26 Cash generated from operations 2025 2024
£ £
Deficit for the year (601,378) (493,352)
Adjustments for:
Investment income recognised in statement of financial activities (52,820) (69,931)
Depreciation and impairment of tangible fixed assets 12,534 9,228
Movements in working capital:
Decrease in stocks 8,511 9,042
Decrease in debtors 107,673 1,986,481
(Decrease) in creditors (1,139,016) (2,143,549)
Increase in deferred income 19,358 12,682
Cash absorbed by operations (1,645,138) (689,399)

27 Analysis of changes in net funds

During the year the charity had no borrowings or obligations under finance leases. The changes in net funds of the charity therefore solely comprise of cash and cash equivalents.